- Health Spotlight's Mantle Cell Lymphoma Insights
- Posts
- Mantle Cell Lymphoma Insights
Mantle Cell Lymphoma Insights
Diagnosis to empowerment: questions to ask and steps to take after being diagnosed with MCL
Liam Ball
January 16, 2025
Exclusive ReportDiagnosis to empowerment: questions to ask and steps to take after being diagnosed with MCLAllMyHealth, the platform that supports rare disease communities, has written a report that guides individuals diagnosed with Mantle Cell Lymphoma (MCL) through understanding their diagnosis, exploring treatment options, and taking proactive steps toward empowerment and hope. It provides clear information on how MCL is diagnosed, the various treatment avenues available, and essential questions to discuss with healthcare providers. The report also highlights inspiring stories of resilience, offers strategies for managing daily life with MCL, and connects readers with valuable support groups and resources. Additionally, it covers the latest research developments and discusses the prognosis for MCL patients, empowering those affected to make informed decisions and live fulfilling lives despite their diagnosis. View the Full ReportThe report is available for free online on the AllMyHealth website. www.allmyhealth.io/report  |
Top StoriesNo ASCT Needed After First CR in MCL Patients, Says Dr. FenskeDr. Fenske discusses the omission of autologous stem cell transplantation (ASCT) in mantle cell lymphoma patients after achieving their first complete remission and undetectable minimal residual disease. This approach is being considered due to advances in treatment and the potential for improved outcomes without the need for ASCT. Read More →New BTK Degraders Offer Hope for Patients with Pretreated B-Cell CancersBTK degraders are being developed to treat patients with pretreated B-cell malignancies, including mantle cell lymphoma, by targeting and degrading the BTK protein more effectively than current inhibitors. These new treatments aim to address the unmet needs of patients who have not responded well to existing therapies. Read More →JW Therapeutics' Carteyva Gains Breakthrough Status in China for Lymphoma TreatmentJW Therapeutics has received Breakthrough Therapy Designation in China for Carteyva, a treatment for relapsed or refractory adult large B-cell lymphoma. This designation could speed up the approval process for this potential therapy, which may also have implications for other types of lymphomas like mantle cell lymphoma. Read More → |
Latest ResearchRecent advancements in immunotherapies have significantly impacted the treatment of mantle cell lymphoma (MCL). Bisio et al. (2025) highlight the role of bispecific antibodies (BsAbs) as promising "off-the-shelf" immunotherapies. These therapies have shown substantial activity against heavily pretreated B-cell non-Hodgkin lymphomas, including MCL, with a manageable toxicity profile. BsAbs can target various cell-surface antigens, offering new avenues for treatment. |